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Photodynamic therapy (PDT) with aminolevulinic acid (ALA) to treat nodular basal cell carcinoma (BCC) has been shown
to be beneﬁcial. The success rate of ALA-PDT in the treatment of nodular BCC is dependent on optimal penetration of the
photosensitizing agent and subsequent PpIX production. To enhance topical delivery of drugs intradermally, a needleless jet
injection (NLJI), which employs a high-speed jet to puncture the skin without the side eﬀects of needles, was used in one patient
with recurrent BCC of the nose. Photoactivation was then performed using red light emitting diode [CW @λ 630nm, irradiance
50mW/cm2, total ﬂuence 51J/cm2] for 17 minutes. Excellent cosmesis was obtained. Asidefrom mild crustingpresent for six days,
no other adverse signs were noted. Clinically, there was no recurrent lesion up two years postintervention. Additional studies in
larger samples of subjects are needed to further evaluate this promising technique.
1.Introduction
Basal cell carcinoma (BCC) is the most frequent type of
skin cancer in humans [1, 2]. Nodular variant is the most
common form and usually presents as a round, pearly, ﬂesh-
colored papule with overlying small blood vessels. As it
expands, it often ulcerates centrally, leaving a raised, pearly
border with telangiectases. They are often seen in sunlight-
exposed areas and on actinic damaged skin. Although it
is rarely life-threatening, if left untreated, it can produce
local destruction, cause bleeding, and be disﬁguring. More-
over, large and longstanding tumours may metastasize into
regional lymph nodes and surrounding tissues and bones.
Hence, these lesions must be treated readily.
A wide range of treatment options exist to treat nodular
BCCs (e.g., cryotherapy, Imiquimod 5% cream, laser, and
radio therapies), yet, surgical excision and Mohs micro-
graphic surgery remain the gold standard treatments for this
condition. Unfortunately, postoperative scars are often visi-
ble and undesirable on areas such as the face. Photodynamic
therapy (PDT) is a treatment modality that is increasingly
used in dermato-oncology as an alternative to surgery
to treat nodular BCC. PDT is based on photochemical
reactions mediated through the interaction of light, oxygen,
and a photosensitizing molecule (e.g., aminolevulinic acid
[ALA]) induced protoporphyrin IX (PpIX) production,
during which cytotoxic reactive oxygen species are formed
causingdamage(necrosis,apoptosis)tothetargetstructures.
Results from clinical research suggest that topical PDT is
eﬃcacious in nodular BCC [3–6] and conveys the advantage
over surgery of better cosmesis [7–11].
The comparative outcome of excision surgery versus
topical-PDT (ALA or methyl aminolevulinate [MAL]) was
documented in three randomized clinical trials in primary
nodular BCC [8–11]. In all studies, the lesions were prepared
with superﬁcial curettage or debridement. The photosensi-
tizing agent (20% ALA cream or 160mg/g of MAL cream)
was then applied to the lesion area and predeﬁned margin,
with a light-occlusive dressing for an incubation period that
lasted between 3 and 6 hours. Across the studies, diﬀerent2 Journal of Skin Cancer
light sources were used to activate the photosensitizer in
the red spectrum (570 to 730nm), in order to improve
tissue penetration, for a total dose of 75J/cm2 or 125J/cm2.
PatientsreceivedeitheroneortwocyclesofPDT,andinsome
trials, PDT was repeated after 3 months if there was evidence
of residual lesions. Short-term (3 months) results for clear-
ance rate revealed no signiﬁcant diﬀerence between topical-
PDT and surgery. Long-term followups (up to ﬁve years),
however, indicated superior lesional response of surgery over
PDT overall, although PDT was also deemed eﬃcacious and
exhibited a more favourable cosmetic outcome. Diﬀerential
eﬃcacy of MAL-PDT versus ALA-PDT was not assessed in
these trials but one further study conducted by Kuijpers et
al. (2006) [12] did not observe any diﬀerences in short-term
eﬃcacy (8 weeks) between these agents, suggesting that both
ALAandMALcanbeequallyusedastopicalphotosensitizers
in PDT for nodular BCC. Overall, the use of topical-PDT
withredlightappearstobeareasonabletreatmentoptionfor
nodular BCC, and in particular, in situations where surgery
may be a suboptimal treatment choice [13, 14].
One possible limitation of PDT in nodular BCC is
the penetration depth of the photosensitizer into the thick
tumourvolume,whichcanimpactsubsequentPpIXproduc-
tion levels and treatment eﬃcacy [15, 16]. The application
of ALA intralesionally, as opposed to topically, has been
suggested as a mean to increase the penetration of photo-
sensitizers. Recent research has reported higher ﬂuorescence
and PpIX levels after the intracutaneous administration of
ALA in contrast to conventional topical application [17,
18]. The use of traditional needles, however, may lead to
profound vascular compromise with possible vasoconstric-
tion, deep purpura, necrosis, and infection and cause pain
[19]. An alternative technique to enhance delivery of drugs
intradermally is the needleless jet injection (NLJI) which
employs a high-speed jet to puncture the skin and distribute
the photosensitizer more evenly without the side eﬀects of
needles [20]. The potential of NLJI for the ﬁeld of ALA-
PDT has recently been highlighted by a preliminary in vitro
investigation using a cross-linked hydrogel as a transparent
skin model [21].
This case study aimed at assessing the in vivo human
eﬃcacy of NLJI ALA-PDT with red light (630nm) in the
treatment of a patient with recurrent nodular BCC of the
nose.
2.MaterialsandMethods
2.1. Case Description. The patient was a 53-year old female
type I Caucasian with recurrent nodular BCC of the nose
aftertwounsuccessfulexcisionalsurgeriesdonebyaqualiﬁed
plasticsurgeonwith5mmmargins.Thediagnosisofnodular
BCC was conﬁrmed by histopathological examination. Her
past medical history indicated varicose veins and face-lift
surgery. She was not taking any medication prior to and after
the procedure. The patient presented a ﬁbrotic translucent
lesion of 5,5mm diameter with telangiectasia and central
atrophy on the left ala of her nose. Given the recurrences
after surgery, the size and location of the lesion, PDT
with intradermal administration of ALA was considered
for this patient. Data was collected in accordance with the
Declaration of Helsinki and the Principles of Good Clinical
Practice.
2.2. Procedure. An alcohol swab was used to clean the
injection site before injection. A MadaJet Medical Injector
(MADA Inc, Carlstadt, NJ) was used to deliver a high
pressure spray of 0.4cc, 20% ALA solution intradermally
into the lesion (Figure 1). After an incubation period of
one hour, the area was illuminated with red light emitting
diode [CW @ λ 630nm, irradiance 50mW/cm2,t o talﬂ ue n c e
51J/cm2] for 17 minutes. Before returning home, the patient
was instructed on posttreatment skin care, which included
applying topical fusidic acid cream twice a day, a plain
moisturiser, sun avoidance, and the use of a sunscreen (SPF
30).
2.3. Clinical Assessments. Assessments of the lesion by means
of visual analysis of digital photographs were carried out by
two blinded physicians. Digital photographs (Canon Dual
FlashEOS10D,Canon,Tokyo,JapanwithEXSIGMA50mm
1:2.8 macrolens, Sigma, Aizu, Japan) were taken at each visit
maintaining as much as possible identical ambient lighting,
pose, and camera angles. The lesion was assessed for clinical
and morphological aspects. Raters assessed the lesion for
degree of improvement from baseline to Month 6, 12, and
24 using a 5-point scale (0= none; 1= mild; 2= moderate;
3= good; 4= excellent). Raters also assessed cosmetic outcome
at Month 6, 12, and 24 using a 4-point scale as follows:
(1) excellent: no scarring, atrophy, or induration and slight
or no redness or change in pigmentation compared with
adjacent skin; (2) good: no scarring, atrophy, or induration
and moderate redness or increase in pigmentation compared
with adjacent skin; (3) fair: slight to moderate occurrence
of scarring, atrophy, or induration; (4) poor: extensive
occurrence of scarring, atrophy, or induration [22]. In
addition, raters were asked to assess the overall cosmetic
outcome using a 4-point scale (1= poor; 2= fair; 3= good; 4=
excellent) at Month 6, 12, and 24.
2.4. Adverse Eﬀects Monitoring. Adverse reactions were
assessed at each visit, including signs of erythema, oede-
ma, hematoma, ulcer scaling/crusting, bronzing, textural
changes, hyperpigmentation, and hypopigmentation.
2.5.PatientSatisfaction. Atthelastfollowupvisit,thepatient
was asked to rate her satisfaction level with the treatment
results.
3. Results and Discussion
Lesion evaluations by two blinded clinicians revealed signif-
icant improvement for clinical and morphological aspects
over time. The degreeofimprovement frombaselinewasrated
as being moderate to good ( s c o r e so f2a n d3 )a tM o n t h6 ,
good ( s c o r e so f3 )a tM o n t h1 2 ,a n dexcellent (scores of 4)
at Month 24 (Figure 2(a)). Cosmetic outcome was deemedJournal of Skin Cancer 3
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Figure 1: Experimental procedure. (a) Intradermal administration of ALA with a MadaJet medical injector; (b) lesion immediately post-
Madajet and prior to the PDT procedure; (c) lesion after the PDT procedure.
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Figure 2: Results from the clinical assessments by two blinded physicians for (a) the degree of improvement from baseline, (b) the cosmetic
outcome, and (c) overall cosmetic outcome at Month 6, 12, and 24.
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Figure 3: Treatment area pre-treatment (Pre), at day 3 (D3) and month 6 (M6), Month 12 (M12), and Month 24 (M24) post-PDT.4 Journal of Skin Cancer
progressively better between Month 6 and Month 24, at
which timepoint it was appraised as excellent (scores of 1),
deﬁned as no scarring, atrophy, or induration and slight
or no redness or change in pigmentation compared with
adjacent skin (Figure 2(b)). Moreover, the overall cosmetic
outcome was judged to be good (scores of 3) at Month 6
and excellent ( s c o r e so f4 )a tM o n t h1 2a n d2 4( Figure 2(c)).
Finally,clinical appraisalrevealedthattherewasnorecurrent
lesion up two years postintervention. Figure 3 depicts digital
photographs of the treatment area pretreatment and up to
Month 24 post-PDT.
Theprocedurewasgenerallywelltoleratedbythepatient,
aside from a slight but bearable sensation of heat during
photoactivation. With the exception of mild crusting present
for six days, no other adverse signs, such hematoma or ulcer,
were noted. Clinically, there was no recurrent lesion up to
Month 24. Histological conﬁrmation of BCC clearance was
not obtained as the patient did not give consent to the skin
biopsy procedure. The patient’s satisfaction level with the
treatment was extremely high.
4. Conclusion
Nodular BCC is a common form of skin cancer and
must be treated readily as it can invade surrounding areas
and cause signiﬁcant destruction and disﬁgurement. In the
present case, ALA-PDT with NLJI was used to directly
deliver the photosensitizer into the lesion, to enhance PDT
eﬀects. This approach proved to be remarkably eﬀective and
well tolerated with no unusual adverse reactions and no
recurrence two years postintervention in this patient with a
large and high risk lesion.
The selection of this technique had several advan-
tages over more conventional methods for this particular
patient. For one, this method did not necessitate mechanical
impairment of the skin or removing the stratum corneum
which can create discomfort for patients and complicate
future outpatient treatments. In addition, unlike previously
reported data with intracutaneous administration of ALA
withtraditionalneedles,noperceptiblevascularcompromise
leading to necrosis was observed in the present case [19].
Moreover, the patient was able to avoid Mohs micrographic
and extensive reconstructive surgery of the nose.
Such a delivery method may be considered for recurrent
lesions conﬁned to surgically tricky or complex anatomical
areas in selected patients. This technique may not be
suitable, however, to treat large areas with multiple lesions
at once, where standard PDT and other approaches or their
combination would be more appropriate. The choice of the
best possible procedure for a given patient is dependent on
the type, size, and location of the lesion. It should be noted
that, in general and for the nodular subtype in particular,
surgical excision remains the treatment of choice to treat
BCCs [13].
Whatever the chosen approach, biopsies are recom-
mended to conﬁrm the diagnosis and determine the his-
t o l o g i c a ls u b t y p e ,a sw e l la st od o c u m e n tl e s i o nc l e a r a n c e
post-intervention. The post-PDT histological conﬁrmation
was unfortunately not possible for this patient. While BCCs
are well recognised clinically, and results from clinical trials
generally show agreement between clinical and histological
assessmentsoftumours[23],theneedforcautiouslong-term
followups in this patient is warranted.
The results obtained in this case are encouraging;
however, supplementary studies in larger samples of patients
and in the long-term are needed to further evaluate this
promising technique. Future controlled studies are also
necessary in order to determine if other photosensitizers,
light sources, and wavelengths would procure added beneﬁts
to patients with an optimal clinical eﬃcacy/side eﬀects ratio.
Other types of lesions, such as superﬁcial BCC, Bowen’s, and
squamous cell carcinoma, could also potentially beneﬁt from
the use of this novel method and could be the object of
additional trials.
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